Profil de l'entreprise pour ONCIMMUNE HLDNGS Action
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
Analyse IA de ONCIMMUNE HLDNGS
Cliquez sur l’une des analyses ci-dessous pour obtenir des informations instantanées de l’IA via finAgent